Adrenocorticotropic Hormone for Childhood Nephrotic Syndrome: The ATLANTIS Randomized Trial.

Clin J Am Soc Nephrol 2018 12 15;13(12):1859-1865. Epub 2018 Nov 15.

Department of Pediatrics, Emory and Children's Pediatric Institute, Atlanta, Georgia.

Background And Objectives: There is renewed interest in adrenocorticotropic hormone (ACTH) for the treatment of nephrotic syndrome. We evaluated the efficacy and safety of ACTH in children with frequently relapsing or steroid-dependent nephrotic syndrome in a randomized trial.

Design, Setting, Participants, & Measurements: Participants aged 2-20 years old with frequently relapsing or steroid-dependent nephrotic syndrome were enrolled from 16 sites in the United States and randomized 1:1 to ACTH (repository corticotropin injection) or no relapse-preventing treatment. ACTH treatment regimen was 80 U/1.73 m administered twice weekly for 6 months, followed by 40 U/1.73 m administered twice weekly for 6 months. The primary outcome was disease relapse during the first 6 months. Participants in the control group were offered crossover to ACTH treatment if they relapsed within 6 months. Secondary outcomes were relapse after ACTH dose reduction and treatment side effects.

Results: The trial was stopped at a preplanned interim analysis after enrollment of 31 participants because of a lack of discernible treatment efficacy. Fourteen out of 15 (93%) participants in the ACTH arm experienced disease relapse in the first 6 months, with a median time to first relapse of 23 days (interquartile range, 9-32), compared with 15 out of 16 (94%) participants and at a median of 21 days (interquartile range, 14-51) in the control group. There was no difference in the proportion of relapsed patients (odds ratio, 0.93; 95% confidence interval, 0.05 to 16.40; >0.99) or time to first relapse (hazard ratio, 1.03; 95% confidence interval, 0.50 to 2.15; =0.93). Thirteen out of 16 participants in the control group crossed over to ACTH treatment. Three out of 28 participants completed 12 months of ACTH treatment; the others exited the trial because of frequent relapses or side effects. There were no disease relapses after ACTH dose reduction among the three participants. Most side effects were mild and similar to side effects of corticosteroids.

Conclusions: ACTH at 80 U/1.73 m administered twice weekly was ineffective at preventing disease relapses in pediatric nephrotic syndrome.

Download full-text PDF

Source
http://cjasn.asnjournals.org/lookup/doi/10.2215/CJN.06890618
Publisher Site
http://dx.doi.org/10.2215/CJN.06890618DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302334PMC
December 2018
64 Reads

Publication Analysis

Top Keywords

acth treatment
20
nephrotic syndrome
20
u/173 administered
12
control group
12
side effects
12
administered weekly
12
acth
11
participants
9
dose reduction
8
participants control
8
three participants
8
disease relapses
8
steroid-dependent nephrotic
8
acth dose
8
relapsing steroid-dependent
8
frequently relapsing
8
confidence interval
8
95% confidence
8
relapse months
8
treatment
8

References

(Supplied by CrossRef)
Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.
Pravitsitthikul et al.
Cochrane Database Syst Rev 2013
The management of the nephrotic syndrome.
Riley et al.
Bull N Y Acad Med 1952
Effect of ACTH in children with the nephrotic syndrome.
Barnett et al.
Pediatrics 1952
Adrenocorticotrophic hormone (ACTH) therapy of the nephrotic syndrome in children.
Metcoff et al.
Pediatrics 1952

Similar Publications